Maravai LifeSciences (MRVI) presented at the Jefferies Global Healthcare Conference, outlining plans to expand beyond its CleanCap product into a broader mRNA development platform. The company said demand is improving across biopharma, though new product adoption and China expansion will take time to generate revenue.

Q3 2024 enterprise revenue grew 10%, with the mRNA segment rising 28% and Cygnus growing 8%. The discovery business jumped 27% after gains of 5% and 15% in prior quarters, and the company landed more than 185 research customers for ModTail, its major new mRNA platform launched in 2023. Management expects a GMP version of ModTail in late 2024, with meaningful revenue arriving in the second half of 2027 after customer qualification.

Gross margins expanded about 1,600 basis points during 2024 and are targeted to move above 60% in the near term. Incremental EBITDA margins stand at about 70% per additional revenue dollar, with long-term EBITDA margins expected in the mid-20s or higher. The 12-month gross margin stands at 40%, with 11% revenue growth over the same period.

TriLink accounts for about 65% of revenue, with mRNA representing 35% of sales and expected to reach low double-digit growth as commercial revenue builds in 2028 and 2029. Cygnus makes up 35% of revenue and is growing at mid-single digits. Jimmy, Maravai's commercial executive, said ModTail could become larger than CleanCap in commercial value. More than 90% of ModTail sales include CleanCap or other reagents.

The company has no revenue from China currently and expects little contribution in 2025, though it has hired a new commercial leader there. Management also said it is deploying artificial intelligence across manufacturing operations using hundreds of proprietary data points. MRVI shares fell 2.91% to $7.185, within their 52-week range of $2.80 to $9.42, but have surged 122% over the past year. Market capitalization stands at $1.92 billion.

Investors should monitor MRVI for ModTail's GMP launch timing and Q2 2027 results to track meaningful revenue from the product.